When Henry Molaison lost the ability to form new memories after experimental brain surgery in 1953, he became one of neuroscience’s most studied patients—living proof of the hippocampus’s role in memory. Now, decades later, that same brain region is helping unlock a new frontier: how we control cravings for food, alcohol, and drugs. New research reveals that GLP-1 drugs like Ozempic and Wegovy don’t just quiet hunger—they act on a precise brain circuit involving the lateral septum, a region once known only for curbing aggression, to reduce compulsive consumption of rewarding substances.
This discovery matters because it shifts our understanding of addiction from a dopamine-only story to one rooted in memory and mental imagery. For years, scientists focused on the brain’s dopamine pathways—the ventral tegmental area and nucleus accumbens—as the epicenter of reward. But these areas lack sufficient GLP-1 receptors, leaving a mystery: how do these drugs curb cravings? The answer lies upstream, in the lateral septum, where neurons integrate spatial and temporal information from the hippocampus and overlay it with value—essentially asking, ‘What is good here and now?’ This region then communicates with dopamine centers, shaping desire before it becomes action.
Crucially, the lateral septum is rich in GLP-1 receptors. When drugs like Ozempic activate them, they appear to dampen the vivid mental imagery that fuels cravings—whether for a cheeseburger or a cold beer. Human trials show that people taking GLP-1 agonists reduce alcohol consumption by up to 30%, while preclinical studies demonstrate decreased use of cocaine, amphetamines, opiates, and nicotine in animal models. Originally developed to treat type 2 diabetes by regulating blood sugar, these drugs have already transformed obesity care, with some patients losing as much weight as they would after bariatric surgery. Now, their potential extends far beyond metabolism.
The implications are profound. If we can target the brain’s reward-mapping system with precision, we may finally have a tool to break the cycle of addiction—not by suppressing pleasure, but by recalibrating how the brain imagines it. This isn’t just about pharmaceuticals; it’s about rewiring the mental scripts that drive destructive behaviors. As research advances, the lateral septum could become a new focal point for therapies that treat both obesity and substance use disorders.
For the millions struggling with addiction or compulsive eating, this science offers more than hope—it offers a map. And for the first time, we’re learning how to read it.